although
feasibl
oral
tacrolimu
administr
presenc
jejunostomi
alreadi
report
studi
monitor
tacrolimu
trough
blood
level
analyz
detail
either
jejunostomi
closur
report
experi
patient
underw
liver
transplant
proxim
jejunostomi
construct
day
prior
second
transplant
administ
tacrolimu
predominantli
oral
rout
less
frequent
receiv
jejunostomi
aim
paper
discuss
administr
strategi
whether
differ
method
could
suitabl
case
report
highlight
jejunostomi
period
tacrolimu
dose
requir
maintain
trough
concentr
within
therapeut
rang
four
time
higher
administ
closur
jejunostomi
observ
increas
dosenorm
trough
concentr
dntc
valu
tacrolimu
administ
consecut
day
jejunostomi
compar
oral
administr
indic
rel
bioavail
tacrolimu
increas
moreov
return
oral
administr
subsequ
dntc
valu
halv
highlight
reduct
tacrolimu
bioavail
thu
case
administr
jejunostomi
could
appropri
summari
although
feasibl
oral
tacrolimu
administr
presenc
jejunostomi
alreadi
report
studi
monitor
tacrolimu
trough
blood
level
analyz
detail
either
jejunostomi
closur
report
experi
patient
underw
liver
transplant
proxim
jejunostomi
construct
day
prior
second
transplant
administ
tacrolimu
predominantli
oral
rout
less
frequent
receiv
jejunostomi
aim
paper
discuss
administr
strategi
whether
differ
method
could
suitabl
case
report
highlight
jejunostomi
period
tacrolimu
dose
requir
maintain
trough
concentr
within
therapeut
rang
four
time
higher
administ
closur
jejunostomi
observ
increas
dosenorm
trough
concentr
dntc
valu
tacrolimu
administ
consecut
day
jejunostomi
compar
oral
administr
indic
rel
bioavail
tacrolimu
increas
moreov
return
oral
administr
subsequ
dntc
valu
halv
highlight
reduct
tacrolimu
bioavail
thu
case
administr
jejunostomi
could
appropri
elsevi
masson
sa
right
reserv
larg
variabl
rate
absorpt
absolut
bioavail
oral
administ
tacrolimu
previous
report
gener
bioavail
poor
approxim
rang
although
feasibl
oral
tacrolimu
administr
presenc
jejunostomi
alreadi
report
studi
monitor
tacrolimu
trough
blood
level
analyz
detail
either
jejunostomi
closur
yet
report
tacrolimu
intak
jejunostomi
evalu
trough
blood
level
report
experi
patient
underw
two
liver
transplant
jejunostomi
construct
day
second
transplant
administ
tacrolimu
predominantli
oral
rout
aim
paper
discuss
administr
strategi
appli
question
whether
anoth
method
could
suitabl
februari
male
patient
underw
liver
transplant
develop
progress
liver
failur
caus
erythropoiet
protoporphyria
immunosuppress
achiev
low
dose
corticosteroid
tacrolimu
adjust
maintain
trough
blood
level
within
rang
ngml
februari
februari
graft
function
well
march
patient
present
alter
clinic
statu
chronic
reject
diagnos
april
mesenter
ischemia
associ
lactic
acidosi
suspect
lactic
acid
mmoll
lipas
uil
ph
disprov
laparotomi
nevertheless
proxim
jejunostomi
caecostomi
perform
monitor
statu
digest
mucou
membran
renal
function
worsen
dialyz
regist
liver
transplant
wait
list
april
second
transplant
achiev
follow
day
reoper
perihepat
hematoma
anemia
hepat
cytolysi
sever
acut
respiratori
syndrom
follow
recurr
pneumopathi
caus
multiresist
klebsiella
pneumonia
atelectasi
result
tracheotomi
slow
difficult
mechan
respiratori
wean
although
clinic
statu
improv
day
follow
transplant
biolog
result
show
chronic
anemia
one
month
transplant
requir
repeat
blood
transfus
liver
function
deterior
addit
activ
cytomegaloviru
cmv
infect
occur
june
patient
underw
oper
new
perihepat
hematoma
drain
periton
caviti
juli
caecostomi
close
august
underw
closur
jejunostomi
septemb
began
feed
oral
without
residu
wean
parenter
enter
nutrit
day
later
transplant
immunosuppress
begun
tacrolimu
mgkg
per
day
mycophenol
mophetil
gday
lowdos
steroid
administr
rout
record
daili
tacrolimu
dose
administ
oral
remain
dose
given
jejunostomi
differ
infecti
episod
receiv
success
fluconazol
caspofungin
juli
simultan
success
oral
valganciclovir
intraven
ganciclovir
tigecyclin
fosfomycin
erythromycin
ad
prokinet
agent
may
may
tacrolimu
trough
blood
level
measur
morn
administr
tacrolimu
enzymemultipli
immunoassay
techniqu
emit
evalu
rel
bioavail
tacrolimu
use
dosenorm
trough
concentr
dntc
calcul
follow
dntc
ngday
per
mgml
trough
blood
level
ngml
oral
dose
mgday
first
liver
transplant
patient
discharg
daili
tacrolimu
dose
mgday
mgkg
dntc
rang
ngday
per
mgml
march
averag
dntc
ngday
per
mgml
evolut
daili
tacrolimu
dose
administ
second
transplant
april
septemb
subsequ
measur
trough
level
shown
fig
tacrolimu
administ
jejunostomi
six
occas
length
occas
day
n
day
n
day
n
tabl
show
dntc
valu
calcul
day
administr
jejunostomi
second
transplant
discharg
distinguish
three
period
first
april
june
unstabl
period
character
infecti
episod
renal
dysfunct
requir
dialysi
alter
liver
function
low
dose
tacrolimu
high
correspond
trough
blood
level
period
daili
tacrolimu
dose
vari
mg
mg
trough
concentr
exceed
ngml
twice
first
instanc
due
drugdrug
interact
erythromycin
second
instanc
ascrib
transitori
liver
dysfunct
due
cmv
infect
perihepat
hematoma
remov
second
period
june
august
patient
gener
statu
improv
requir
progress
increas
daili
dosag
mg
stabil
month
closur
jejunostomi
mg
per
day
third
period
began
closur
jejunostomi
observ
rapid
increas
trough
level
necessit
withhold
tacrolimu
day
week
closur
jejunostomi
dose
taper
mgday
correspond
reduct
compar
daili
dose
administ
closur
patient
discharg
daili
dose
mg
mgkg
per
day
dntc
rang
ngday
per
mgml
septemb
averag
dntc
ngday
per
mgml
daili
dose
dntc
similar
obtain
discharg
first
transplant
case
report
highlight
jejunostomi
period
tacrolimu
dose
requir
maintain
trough
concentr
within
therapeut
rang
proxim
stoma
open
percent
absorpt
increas
first
patient
second
stoma
close
hasewaga
et
al
report
similar
result
girl
liver
transplant
oral
administr
presenc
jejunostomi
observ
decreas
bioavail
presenc
jejunostomi
dose
requir
closur
time
dose
requir
closur
previous
publish
data
provid
explan
observ
human
presystem
metabol
tacrolimu
gastrointestin
isoenzym
remov
gut
lumen
pglycoprotein
transport
extens
upper
small
intestin
major
site
firstpass
metabol
express
highest
duodenum
jejunum
decreas
toward
distal
region
data
suggest
increas
dose
necessari
overcom
presystem
metabol
tacrolimu
allow
passiv
diffus
upper
small
intestin
regard
decis
make
process
inform
given
tabl
appear
unequ
inform
variat
observ
five
occas
tacrolimu
administ
day
day
lack
reliabl
take
account
patient
statu
precis
emit
intraindividu
variabl
administr
tacrolimu
consecut
day
jejunostomi
may
reliabl
increas
dntc
valu
indic
rel
bioavail
tacrolimu
increas
absenc
drug
interact
oral
rout
begun
subsequ
dntc
valu
halv
highlight
reduct
tacrolimu
bioavail
observ
rais
question
whether
adopt
strategi
administ
tacrolimu
oral
rout
optim
one
analysi
previous
publish
anim
studi
human
case
report
suggest
administr
jejunostomi
may
appropri
cost
effect
administ
drug
jejunostomi
consid
bypass
proxim
small
intestin
consequ
reduc
surfac
area
avail
absorpt
howev
cyp
content
greater
proxim
small
intestin
bypass
segment
also
result
rel
larg
reduct
overal
gastrointestin
metabol
activ
may
increas
bioavail
drug
subject
firstpass
metabol
intestin
two
oppos
process
may
differ
degre
affect
bioavail
oral
administ
drug
depend
drug
individu
patient
characterist
patient
low
gastrointestin
metabol
capac
therefor
like
achiev
high
system
exposur
restrict
absorpt
area
could
potenti
reduc
bioavail
patient
high
gastrointestin
metabol
activ
restrict
absorpt
area
could
potenti
increas
bioavail
specul
support
previous
describ
case
report
data
togeth
fact
day
tacrolimu
administr
jejunostomi
studi
dntc
valu
higher
obtain
previou
subsequ
tacrolimu
dose
administ
oral
rout
suggest
patient
administ
tacrolimu
oral
rout
like
optim
strategi
conclus
administr
tacrolimu
oral
rout
patient
jejunostomi
necessit
increas
dose
two
fourfold
administ
suggest
patient
present
high
presystem
metabol
activ
upper
small
intestin
case
administr
jejunostomi
could
appropri
studi
warrant
confirm
hypothesi
